Annual report pursuant to Section 13 and 15(d)

CONDENSED STATEMENTS OF OPERATIONS

v3.22.1
CONDENSED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating expenses:    
Research and development $ 49,864 $ 37,237
Research and development - licenses acquired 5,842 10,064
General and administrative 11,017 9,505
Total operating expenses 66,723 56,806
Loss from operations (66,723) (56,806)
Other income (expense)    
Interest income 368 708
Interest expense (15) (3,917)
Total other income (expense) 353 (3,209)
Net Loss $ (66,370) $ (60,015)
Net loss per common share outstanding, basic and diluted $ (0.76) $ (1.14)
Weighted average number of common shares outstanding, basic and diluted 87,885,235 52,588,781